| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |